Fig. 3From: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancerKaplan-Meier estimates (N = 22) of (a) PFS and (b) OSBack to article page